latest news

iTeos Therapeutics Completes $75 Million Series B Financing

Gosselies, Belgium – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the completion of an oversubscribed $75 million (€64 million) Series B financing led by MPM Capital, with participation from additional new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All existing investors also participated in this financing round including Fund +, VIVES II and SRIW, as well as SFPI. Read the official press release here.